Future work should evaluate etiologic and survival associations for TP53 based on RNA-based signatures particularly by race where black women with ER+, HER2- disease have worse outcomes than white women.28,29 An advantage of the current method is that measuring RNA through methods like NanoString assays can simultaneously measure tumor subtype (e.g., PAM50) and TP53 mutant-like status in both fresh frozen and FFPE samples. This evidence concerns the gene ERBB2 and neoplasm.